ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: FR-PO182

Shorter vs. Longer Corticosteroid Duration and Recurrent Immune Checkpoint Inhibitor-Associated AKI

Session Information

Category: Onconephrology

  • 1600 Onconephrology


  • Gupta, Shruti, Brigham and Women's Hospital, Boston, Massachusetts, United States
  • García-Carro, Clara, San Carlos Clinical Hospital, Madrid, Spain
  • Sise, Meghan E., Massachusetts General Hospital, Boston, Massachusetts, United States
  • Soler, Maria Jose, Vall d’Hebron University Hospital, Barcelona, Spain
  • Leaf, David E., Brigham and Women's Hospital, Boston, Massachusetts, United States

Group or Team Name

  • ICPi-AKI Consortium

Corticosteroids are the mainstay of treatment for immune checkpoint inhibitor-associated acute kidney injury (ICPi-AKI), but the optimal duration of therapy has not been established. Prolonged use of corticosteroids can cause numerous adverse events and possibly decreased progression-free survival among patients treated with ICPis. We therefore sought to determine whether a shorter duration of corticosteroids was equally efficacious and safe as compared to a longer duration.


We used data from our previously conducted multicenter cohort study of patients diagnosed with ICPi-AKI from 29 centers across 9 countries. We examined whether a shorter duration of corticosteroids (28 days or less) versus a longer duration of corticosteroids (29-84 days) was associated with a higher rate of recurrent ICPi-AKI or death in the 30-day period following completion of corticosteroid treatment.


Of 165 patients treated with corticosteroids, 56 (34%) received a shorter duration of treatment and 109 (66%) received a longer duration. Patients in these two groups were similar with respect to age, sex, race, malignancy type, and baseline kidney function. Five of 56 patients (8.9%) in the shorter duration group and 12 of 109 (11%) in the longer duration group developed recurrent ICPi-AKI or died (Log-rank P=0.90) (Figure A). Nadir serum creatinine in the first 14, 28, and 90 days following completion of corticosteroid treatment was similar in the shorter versus longer duration groups (P=0.40, P=0.56, and P=0.89, respectively) (Figure B).


A duration of corticosteroids of 28 days or less may be safe for patients with ICPi-AKI. However, the findings may be susceptible to unmeasured confounding and further research from randomized clinical trials is needed.